277 results match your criteria: "Centre de pathologie[Affiliation]"
Neuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFAnn Dermatol Venereol
November 2024
Centre de Pathologie génitale et IST, Service de Dermatologie, Hôpital Saint-Louis, Paris, France.
Bull Cancer
January 2025
FSNB Health & Care, 29, rue de Saussure, 75017 Paris, France. Electronic address:
The prognostic of certain cancers improved significantly in recent years thanks not only to the launch of innovative treatments but also to progress made in the diagnostic field. Thus, next-generation sequencing (NGS) became paramount to help characterizing tumors and selecting the most pertinent treatments. The survey conducted by a multi stakeholder committee, at the end of 2022, with 103 actors of the management of cancer patients (public and private centers, labs, prescribers, biologists, pathologists, direction) confirmed the heterogeneity of use of NGS tests across France due to, mainly, the lack of systematic reimbursement of related costs.
View Article and Find Full Text PDFEur J Endocrinol
August 2024
Cancer Research Center of Lyon, Inserm U1052, CNRS UMR5286, Lyon F-69008, France.
Objective: Targeted therapy (TT) with BRAF/MEK inhibitors has emerged as a potential treatment in papillary craniopharyngiomas (PCPs). However, standardized data on large cohorts are lacking. Our study aimed to assess real-life efficacy and safety of BRAF/MEK inhibition in patients with PCPs.
View Article and Find Full Text PDFBirth Defects Res
July 2024
Département de Médecine Génomique Des Maladies Rares, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.
Case Rep Orthop
March 2024
Department of Orthopedics and Traumatology, Centre Hospitalier de Saint-Denis, Hôpital Delafontaine, Saint-Denis, France.
A leiomyoma is a benign smooth muscle tumor that is most commonly found in the uterus. Limited studies have reported leiomyoma of the foot, rendering it an usual finding. We present a case of a 57-year-old female patient who presented to the clinic for a painless mass on the posteromedial side of the right heel.
View Article and Find Full Text PDFAnn Pathol
May 2024
Centre de pathologie et d'imagerie, 14, avenue René Coty, 75014 Paris, France. Electronic address:
Acta Myol
February 2024
Laboratory of Neurogenetics, Parkinson Disease and Cerebrovascular Diseases (LR-12-SP-19), Habib Bourguiba University Hospital, University of Sfax, Tunisia.
Fukutin-related protein (FKRP) mutations cause a broad spectrum of muscular dystrophies, from a relatively mild limb-girdle muscular dystrophy type 9 (LGMDR9) to severe congenital muscular dystrophy (CMD). This study aims to report two siblings belonging to a non-consanguineous Tunisian family harboring a novel compound heterozygous variant and presenting a mild LGDMR9 phenotype. For mutation screening, massive parallel sequencing was performed, followed by Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) to validate the existence of the discovered variants.
View Article and Find Full Text PDFLife (Basel)
January 2024
Hôpital du Valais, 1951 Sion, Switzerland.
In Switzerland, breast cancer is the leading cancer among women, with breast-conserving surgery (BCS) being the preferred treatment for small tumors. The margin status post-surgery is a critical predictor of local recurrence. Achieving negative margins remains a challenge, leading to re-excision in 20-30% of cases.
View Article and Find Full Text PDFCell Cycle
March 2024
Dipartimento di Medicina Molecolare e Biotecnologie Mediche (DMMBM), Istituto per l'Endocrinologia e l'Oncologia Sperimentale (IEOS) "G. Salvatore", Consiglio Nazionale delle Ricerche (CNR) c/o, Università degli Studi di Napoli "Federico II", Naples, Italy.
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and lethal neoplasms in humans, and just limited progresses have been made to extend patient survival and decrease ATC-associated mortality. Thus, the identification of novel therapeutic strategies for treating ATC is needed. Recently, our group has identified two proteins with oncogenic activity, namely HMGA1 and EZH2, with pivotal roles in ATC cancer progression.
View Article and Find Full Text PDFEur Ann Otorhinolaryngol Head Neck Dis
March 2024
Département de biopathologie, CHU de Montpellier, Montpellier, France.
Objective: To determine the indications for fine-needle cytology and the modalities of frozen section pathological analysis in the management of salivary gland cancer.
Material And Methods: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group according to the formal consensus method.
Mod Pathol
December 2023
Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland. Electronic address:
Tumor cell fraction (TCF) estimation is a common clinical task with well-established large interobserver variability. It thus provides an ideal test bed to evaluate potential impacts of employing a tumor cell fraction computer-aided diagnostic (TCFCAD) tool to support pathologists' evaluation. During a National Slide Seminar event, pathologists (n = 69) were asked to visually estimate TCF in 10 regions of interest (ROIs) from hematoxylin and eosin colorectal cancer images intentionally curated for diverse tissue compositions, cellularity, and stain intensities.
View Article and Find Full Text PDFBlood
December 2023
Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.
Viral hemorrhagic fevers (HF) are a group of acute febrile diseases with high mortality rates. Although hemostatic dysfunction appears to be a major determinant of the severity of the disease, it is still unclear what pathogenic mechanisms lead to it. In clinical studies it is found that arenaviruses, such as Lassa, Machupo, and Guanarito viruses cause HF that vary in symptoms and biological alterations.
View Article and Find Full Text PDFWorld J Urol
September 2023
Urology Department, GRC n°5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.
Purpose: Cytology and cystoscopy, the current gold standard for diagnosing urothelial carcinomas, have limits: cytology has high interobserver variability with moderate or not optimal sensitivity (particularly for low-grade tumors); while cystoscopy is expensive, invasive, and operator dependent. The VISIOCYT1 study assessed the benefit of VisioCyt for diagnosing urothelial carcinoma.
Methods: VISIOCYT1 was a French prospective clinical trial conducted in 14 centers.
J Eur Acad Dermatol Venereol
April 2023
Department of Dermato-Oncology, AP-HP Hôpital Saint-Louis, Paris, France.
Ann Pathol
June 2023
Université de la Sorbonne, Paris, France; Service d'anatomie et cytologie pathologiques, Sorbonne université, hôpital Saint-Antoine, AP-HP, Paris, France.
The two main forms of inflammatory bowel disease (IBD) are ulcerative colitis (UC) and Crohn's disease (CD). Both diseases have inflammatory flare-ups that alternate with periods of remission. The pathologist may examine biopsies of the digestive tract from IBD patients in different contexts: at the time of the initial diagnosis, in the event of a disease flare-up in order to differentiate a flare of the disease from another cause, particularly an infectious one, and during the long term follow-up of the disease in order to detect the occurrence of dysplastic lesions.
View Article and Find Full Text PDFNat Genet
April 2023
Rare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using multiomics factor analysis, we demonstrate that the current World Health Organization classification only accounts for up to 10% of interpatient molecular differences. Instead, the MESOMICS project paves the way for a morphomolecular classification of MPM based on four dimensions: ploidy, tumor cell morphology, adaptive immune response and CpG island methylator profile.
View Article and Find Full Text PDFRev Mal Respir
May 2023
Service de pneumologie, CHU de Pointe-à-pitre/Abymes, route de chauvel, BP 465, 97159 Pointe-à-Pitre, Guadeloupe, France.
Ann Pathol
June 2023
Centre de pathologie Emile Gallé Groupe, Nancy, France. Electronic address:
J Pathol Inform
October 2022
Pathologie, CHU Saint-Louis, APHP, Université Paris Cité, 1 avenue Claude Vellefaux, 75010 Paris, France.
The French Society of Pathology (SFP) organized its first data challenge in 2020 with the help of the Health Data Hub (HDH). The organization of this event first consisted of recruiting nearly 5000 cervical biopsy slides obtained from 20 pathology centers. After ensuring that patients did not refuse to include their slides in the project, the slides were anonymized, digitized, and annotated by expert pathologists, and finally uploaded to a data challenge platform for competitors from around the world.
View Article and Find Full Text PDFNature
December 2022
The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Ann Endocrinol (Paris)
December 2022
Thyroid and Endocrine Tumors Department, Institute of Endocrinology, Pitié-Salpêtrière Hospital AP-HP, Sorbonne University, 75013 Paris, France; Institute of Cancer IUC Sorbonne University GRC N°16, 75013 Paris, France; Centre de Pathologie et d'Imagerie, 14, Avenue René-Coty, 75014 Paris, France.
The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment.
View Article and Find Full Text PDFAnn Endocrinol (Paris)
December 2022
Centre de Pathologie et d'Imagerie, 14 Avenue René Coty, 75014 Paris, France; Thyroid and Endocrine Tumors Department, Pitié-Salpêtrière Hospital APHP, Institute of Cancer IUC, Sorbonne University GRC N°16, 83 Boulevard de l'Hôpital, 75013 Paris, France.
The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment.
View Article and Find Full Text PDFAnn Endocrinol (Paris)
December 2022
Thyroid and Endocrine Tumors Department, Pitié-Salpêtrière Hospital APHP, Institute of Cancer IUC Sorbonne University, Paris, France; Centre de Pathologie et d'Imagerie, 14 Avenue René Coty, 75014 Paris, France.
The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment.
View Article and Find Full Text PDFAdolescents and young adults (AYA) with cancer often fall through gaps between children's and adults' cancer services. They are consequently under-represented in clinical trials, and their survival is often inferior to that of children or adults with the same tumor type; in this paper, we use the example of central nervous system germ cell tumors (CNS-GCT), as a model of AYA tumor to illustrate this challenge. We describe how we have built bridges between pediatric and adult oncology, how this can apply to other types of brain tumors, and discuss ways to promote cancer care in the AYA population.
View Article and Find Full Text PDF